Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma
Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related death in both men and women in the United States. Platinum-based doublet chemotherapy has been a standard for patients with advanced stage disease. Improvements in overall survival and quality of life have been modest. Im...
Saved in:
| Published in: | World journal of clinical oncology Vol. 4; no. 2; pp. 29 - 42 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Baishideng Publishing Group Co., Limited
10-05-2013
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related death in both men and women in the United States. Platinum-based doublet chemotherapy has been a standard for patients with advanced stage disease. Improvements in overall survival and quality of life have been modest. Improved knowledge of the aberrant molecular signaling pathways found in NSCLC has led to the development of biomarkers with associated targeted therapeutics, thus changing the treatment paradigm for many NSCLC patients. In this review, we present a summary of many of the currently investigated biologic targets in NSCLC, discuss their current clinical trial status, and also discuss the potential for development of other targeted agents. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Author contributions: Both authors contributed equally to this work. Telephone: +1-580-5042781 Fax: +1-580-2206118 Correspondence to: Soley Bayraktar, MD, MBA, Departments of Medical Oncology, Mercy Cancer Center, 1220 Hall street, Ardmore, OK 73401, United States. soley.bayraktar@mercy.net |
| ISSN: | 2218-4333 2218-4333 |
| DOI: | 10.5306/wjco.v4.i2.29 |